Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Information (Details)

v3.20.1
Stock-Based Compensation - Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock-Based Compensation    
Available for grant (in shares) 231,941  
Share-based compensation costs recognized $ 776 $ 682
Research and development expense    
Stock-Based Compensation    
Share-based compensation costs recognized 466 453
General and administrative expense    
Stock-Based Compensation    
Share-based compensation costs recognized $ 310 229
Options    
Stock-Based Compensation    
Number of options granted (in shares) 100,000  
Share-based compensation costs recognized $ 768 659
Weighted-average grant-date fair value 1,195  
Remaining unamortized expense $ 3,198  
Remaining unamortized expense period 1 year 2 months 12 days  
Options | BioXcel Corporation    
Stock-Based Compensation    
Share-based compensation costs recognized $ 8 $ 23